FDAnews Drug Daily Bulletin
Pharmaceuticals / Research and Development

Pfizer Ends Global Development of Bococizumab

Nov. 8, 2016

Pfizer has discontinued the global clinical development program for bococizumab, its investigational proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i).

Pfizer has observed an emerging clinical profile that includes an unanticipated reduction of low-density lipoprotein cholesterol (LDL-C) over time, as well as a higher level of immunogenicity and higher rate of injection-site reactions with bococizumab than shown with the other agents in this class.

With the decision to discontinue bococizumab development, Pfizer will halt two ongoing cardiovascular outcome studies.

View today's stories